Justin Walsh
Stock Analyst at Jones Trading
(1.52)
# 3,444
Out of 4,981 analysts
40
Total ratings
38.89%
Success rate
-6.52%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Downgrades: Hold | n/a | $8.59 | - | 2 | Aug 5, 2025 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $3.30 | - | 3 | Jul 3, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $122 → $109 | $52.94 | +105.89% | 9 | Jun 23, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.66 | +357.25% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $4.04 | +197.03% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $5.80 | +417.24% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $49.48 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.19 | +111.95% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $3.89 | +362.72% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $23.76 | +76.77% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $3.48 | +532.18% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.61 | +247.07% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.08 | +549.35% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.94 | +326.21% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.07 | +391.40% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.74 | +934.48% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.66 | +26,406.02% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.45 | +16,667.27% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $39.42 | -49.26% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.80 | +11,042.06% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.57 | +180.11% | 1 | Jan 19, 2022 |
Y-mAbs Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: n/a
Current: $8.59
Upside: -
Theratechnologies
Jul 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.30
Upside: -
Lantheus Holdings
Jun 23, 2025
Maintains: Buy
Price Target: $122 → $109
Current: $52.94
Upside: +105.89%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.66
Upside: +357.25%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $4.04
Upside: +197.03%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $5.80
Upside: +417.24%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $49.48
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.19
Upside: +111.95%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $3.89
Upside: +362.72%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $23.76
Upside: +76.77%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.48
Upside: +532.18%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.61
Upside: +247.07%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.08
Upside: +549.35%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.94
Upside: +326.21%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $4.07
Upside: +391.40%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $1.74
Upside: +934.48%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.66
Upside: +26,406.02%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.45
Upside: +16,667.27%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $39.42
Upside: -49.26%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.80
Upside: +11,042.06%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $3.57
Upside: +180.11%